218 related articles for article (PubMed ID: 23555046)
1. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.
Verreault M; Weppler SA; Stegeman A; Warburton C; Strutt D; Masin D; Bally MB
PLoS One; 2013; 8(3):e59597. PubMed ID: 23555046
[TBL] [Abstract][Full Text] [Related]
2. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
Ramaiah MJ; Kumar KR
Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
[TBL] [Abstract][Full Text] [Related]
3. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells.
Das G; Shiras A; Shanmuganandam K; Shastry P
Mol Carcinog; 2011 Jun; 50(6):412-23. PubMed ID: 21557327
[TBL] [Abstract][Full Text] [Related]
4. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
5. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
7. Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Palumbo S; Tini P; Toscano M; Allavena G; Angeletti F; Manai F; Miracco C; Comincini S; Pirtoli L
J Cell Physiol; 2014 Nov; 229(11):1863-73. PubMed ID: 24691646
[TBL] [Abstract][Full Text] [Related]
8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
10. MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells.
Dong Z; Zou J; Li J; Pang Y; Liu Y; Deng C; Chen F; Cui H
Cancer Med; 2019 Dec; 8(18):7793-7808. PubMed ID: 31691527
[TBL] [Abstract][Full Text] [Related]
11. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
13. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
14. MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
Liu T; Li A; Xu Y; Xin Y
Cancer Med; 2019 Feb; 8(2):751-760. PubMed ID: 30656846
[TBL] [Abstract][Full Text] [Related]
15. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
19. microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells.
Cui Y; Zhao J; Yi L; Jiang Y
PLoS One; 2016; 11(6):e0156915. PubMed ID: 27295037
[TBL] [Abstract][Full Text] [Related]
20. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
